Overview

Hormone Replacement for Premature Ovarian Insufficiency

Status:
Withdrawn
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
The investigators intend to establish feasibility/acceptability of a pilot randomized trial comparing hormone replacement therapy (HRT) and combined oral contraceptives (COCs) in women with premature ovarian insufficiency to estimate differences in quality of life (QOL) and serum hormone assays and markers of bone turnover/cardiovascular risk. At baseline, QOL survey will be administered and serum testing performed. Patients then randomized to HRT or COCs. Repeat testing will be performed after 3 and 6 months.
Phase:
Phase 3
Details
Lead Sponsor:
University of Pennsylvania
Treatments:
Contraceptive Agents
Contraceptives, Oral
Contraceptives, Oral, Combined
Estradiol
Estradiol 17 beta-cypionate
Estradiol 3-benzoate
Estradiol valerate
Ethinyl Estradiol
Hormones
Medroxyprogesterone
Medroxyprogesterone Acetate
Norgestimate
Polyestradiol phosphate
Progesterone
Progestins